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Abstract 
A randomised controlled trial (RCT) is accepted as the best way of assessing the efficacy of a 
treatment. However randomization is sometimes impractical, especially when assessing the ability of 
new diagnostic tests to predict the outcome of a treatment if the latter has shown to be superior to 
placebo already in a previous RCT. Such ‘tests’ may be based on single measurements or 
multivariable scores or other factors that may be studied to assess the external validity of a RCT 
result. The method described here is based on allocating subjects to a control limb if the results of 
the test used to select subjects for the trial are in one range (e.g. on one side of some threshold) and 
allocating subjects to a treatment limb if the results are in a different range (e.g. on the other side of 
a threshold). The results are interpreted by assuming that the distribution of baseline test results in 
those with a subsequent outcome are the same irrespective of whether the subjects with that 
outcome were in the treatment or placebo limbs. The resulting range of likelihood ratios are then 
used in conjunction with the proportion with an outcome in each limited range to estimate the 
proportion with that outcome in the entire range of test results by using a rearrangement of Bayes 
rule. The approach is illustrated with data from a RCT where the diagnostic test was the albumin 
excretion rate, the treatment was an angiotensin receptor blocker and the outcome was biochemical 
nephropathy. When curves are constructed to show the probabilities of an outcome (nephropathy) 
on placebo and treatment for each diagnostic test result by using all the data from the RCT and from 
only the part of the data that would have been available from a ‘segmental’ trial, the results were 
very similar, the small differences being readily explicable due to minor stochastic variation. 
Provided that suitable controls are in place, (e.g. ‘double blinding’) it appears that a ‘segmental’ 
study can predict the result of an RCT. The approach described here has many advantages compared 
to a ‘regression discontinuity design’. 
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1. Introduction 
Randomized controlled trials (RCTs) are accepted as the best way of assessing the efficacy of a 
treatment [1]. It is also important to be able to use controlled trials to choose the best tests 
(including multivariate scores) for identifying who could benefit from that treatment and to establish 
thresholds that reduce the risk of over diagnosis, over-treatment and also under diagnosis and 
under-treatment [2]. It would important to do so for new tests that were not available during an 
original RCT. However, RCTs may not be possible or practical in such situations [3, 4] especially if a 
previous study had showed clear evidence of benefit from treatment compared to placebo. It would 
then be unreasonable or unethical to ask patients to be randomized into a placebo group.  
There are also concerns that too little attention is paid to the external validity of RCTs [5]. There is 
currently much interest in assessing the external validity of RCTs by using ‘real world evidence’ in the 
form of assessments that do not use randomization [6]. The technique of ‘regression discontinuity’ 
[7, 8] has been proposed as a method of evaluating such external validity and as an alternative to 
randomization. However, ‘regression discontinuity’ cannot assess how well different values of a test 
result can predict which patients are likely to have the desired outcome from the treatment and 
control and they have limitations when no single threshold was used as a reason to begin treatment 
so that the rule for doing so is ill-defined or ‘fuzzy’ [7, 8].  
It might be possible to use another novel method to allocate patients to a treatment or control 
without randomization and to interpret the results in different ranges and without necessarily using 
a single threshold to specify the different ranges. It is based on an assumption that the distribution 
of test results in those with a particular outcome are the same irrespective of whether the subjects 
with that outcome were in the intervention or control limb. This ‘assumption of intervention 
independent distributions’ is already the hidden assumption widely used currently to estimate 
absolute risk reduction from relative risk reductions or odds ratios and individual baseline risk [2]. 
The resulting likelihood ratios are then used in conjunction with the proportion with an outcome in a 
specified range to estimate the proportion with that outcome throughout the entire range of tests 
results by using a rearrangement of Bayes rule. This approach might therefore be used to assess 
tests for selecting patients for the treatment and also to assess treatment efficacy. This proposed 
method will be demonstrated using data from a RCT for allocating patients to placebo and treatment 
and comparing the result with using a pre-specified ranges that can be based on a single threshold to 
allocate the patients in an unbiased way. 
2. Methods 
The data used to compare the result of randomizing patients to treatment and control with 
allocation using a ranges were from the IRMA II trial [9, 10]. The aim of that trial was to assess the 
reno-protective efficacy of irbesartan. It was a randomised, placebo-controlled trial. It was 
conducted in 96 centres and 18 countries in 590 hypertensive patients of either sex, aged 30 to 70 
years, and with Type 2 diabetes and persistent micro-albuminuria. A total of 1,469 patients were 
eligible after the enrolment visit. This visit was followed by a three-week run-in (screening) period, 
during which all antihypertensive treatment was discontinued. The BP was measured every week, 
and overnight urine specimens were obtained for the measurement of albumin concentrations on 
three consecutive days at the end of the three-week run-in period. Patients were selected if they 
had persistent hypertension and persistent albuminuria, defined as an albumin excretion rate of 20 
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to 200 mcg/minute in two out of three consecutive overnight urine samples. Persistent hypertension 
was defined as a mean systolic BP >135 mmHg or a mean diastolic BP >85 mmHg, or both, in at least 
two out of three consecutive readings obtained one week apart during the run-in period. Diabetic 
nephropathy was regarded as persistent macro-albuminuria, defined as an albumin excretion rate of 
over 200 mcg/minute in at least two successive samples, and an increase of at least 30% from 
baseline. A total of 590 of the 1,469 screened patients were randomised to groups of placebo, 
irbesartan 150 mg daily and irbesartan 300 mg daily, then followed- up at 3, 6, 12, 18 and 22 to 24 
months. If the BP of any of the patients in the trial rose out of control after starting treatment, 
further antihypertensive treatment was added in the form of a diuretic, beta-blocker or non-
dihydropyridine calcium channel blocker.  
3. Analysis of results 
The object of the analysis was to show that the partial data from a so-called ‘segmental’ controlled 
trial (SCT) that was not based on randomisation can provide enough information to come to the 
same conclusion as the greater amount of data provided by a RCT when assessing the ability of 
diagnostic tests to predict probable treatment outcome. However, in order to maximise the amount 
of data analysed the two ‘segments’ chosen for this particular analysis were adjacent. The first 
‘segment’ was an AER up to the threshold of 80mcg/min and the second ‘segment’ was over the 
threshold of 80mcg/min. In order to perform the calculations we have to establish the following: 
i.  The proportions of patients with an AER up to 80mcg/min at the beginning of the trial 
who develop nephropathy after 2 years of taking placebo  
ii. The proportion of those with AERs over 80mcg/min at the beginning of the trial who 
develop nephropathy after 2 years of taking irbesartan 
iii. In those with an AER up to 80mcg/min at the beginning of the trial and taking placebo, 
the AER values in those who do and do not develop nephropathy within 2 years 
iv. In those with an AER over 80mcg/min at the beginning of the trial and taking irbesartan, 
the AER values in those who do and do not develop nephropathy within 2 years 
From the above and by applying a Bayes rule re-arrangement and the ‘assumption of 
intervention independent distributions’ we estimate the following: 
A. The proportion with nephropathy after 2 years in all those in the placebo limb of the original 
RCT (i.e. with an AER from 20 to200mcg/min) 
B. The proportion with nephropathy after 2 years in all those in the irbesartan limbs of the 
original RCT (i.e. with an AER from 20 to200mcg/min) 
C. The distribution of AER results at the beginning of the trial in those with and without the 
outcome of nephropathy by combining the data from (iii) and (iv) above. 
 
4. The assumption of intervention independent distributions 
The assumption of intervention independent distributions is that the frequency or distribution of 
test results observed at the beginning of a RCT in those with or without a ‘target outcome’ is the 
same irrespective of whether they are on different interventions (e.g. treatment or on placebo). This 
is the underlying assumption that is made to calculate absolute risk reductions based on a particular 
baseline risk or probability from an observed average risk reduction or the odds ratio in a RCT [2]. A 
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well known example is applying the average risk reduction in patients participating in a RCT on 
statins to patients with different baseline risks of cardio-vascular disease. This is based on an 
assumption that the relative risk is constant for all baseline probabilities. However, this is not true. 
Provided that the assumption of intervention independent likelihoods is valid, then it is the odds 
ratio that will be constant for all baseline odds. The relative risk provides a good approximation to 
the odds ratio when it is based on low proportions from a RCT and also when it only applied to 
baseline probabilities that are also low probabilities [2, 11]. 
An ‘explanation’ for the assumption of intervention independent distributions is that a treatment 
reduces the number of patients with the target outcome equally along its distribution range so that 
the distribution of test results in those subjects being removed by treatment from a disease group 
are similar to those in the group originally (and also those left behind). Because of this, the shape of 
the distribution, its mean and standard deviation are assumed to remain the same. Those subjects 
that leave the target population with treatment move into the non-target population (e.g. those 
without nephropathy). The latter population is typically large and will be little changed by the ‘influx’ 
of subjects that have left the disease outcome because of treatment. Consequently, mean and 
standard deviation of results in the ‘non-disease’ outcome stays roughly the same.  
The assumption of intervention independent distributions could be tested in an original RCT to 
assess efficacy of a treatment and if it appears to hold true, be applied to subsequent non-
randomised studies used to explore the external validity of the original RCT or the effect of using 
different baseline measurements on estimating the probabilities of the outcome for different 
baseline results. If the assumption of intervention independent distributions did not apply strongly 
then it might be possible to use a correction factor for subsequent non-randomised studies of 
effectiveness of a treatment. 
A corollary of this assumption of assumption of intervention independent distributions is that if we 
dichotomise the data into ‘low’ (e.g. from patients with an AER up to 80mcg/min and ‘high’ (e.g. 
from those with an AER above 80mcg/min), then the likelihood of a ‘high’ and ‘low’ AER should also 
be the same in those on treatment or placebo (or some other ‘control’ treatment). This in turn 
implies that the difference in response rate will be due to the effect of different treatments creating 
different ‘prior’ probabilities of the outcome (e.g. the prior probability of nephropathy on placebo 
before taking an initial AER level into account).  
 
5. Results 
The numbers developing persistent macro-albuminuria or ‘nephropathy’ at 24 months on placebo 
and irbesartan 150mg and 300mg daily in the randomised IRMA2 RCT are shown in table 1.  
 
Table 1 Proportion of patients developing nephropathy at 24 months on different treatments after 
starting from different baseline urinary albumin excretion rates (AERs) 
 
Table 1    
Baseline AER Placebo Irbesartan 150mg daily Irbesartan 300mg daily 
161 to 200 μg/minute  2/7 = 28.57%  4/13 = 30.77%  1/2 = 50.00% 
121 to 160 μg/minute  9/23 = 39.13%  3/16 = 18.75%  0/11 = 0.00%* 
81 to 120 μg/minute  9/32 = 28.13%  7/33 = 21.12%  4/37 = 10.81% 
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41 to 80 μg/minute  9/57 = 15.79%  5/66 = 7.58%  4/74 = 5.41%† 
20 to 40 μg/minute  1/77 = 1.30%  0/59 = 0%  1/68 = 1.47% 
    
All: 20 to 200 μg/minute  30/196 = 15.30%  19/187 = 10.16%  10/192 = 5.21%# 
 
6. Likelihood distributions 
The mean and standard deviations of the natural log of the AER in patients with and without 
nephropathy who were taking placebo and irbesartan and various combinations of these groups are 
shown in table 2.  
 
Table2: The means and standard deviations of the natural log of the AER (mean of three collection 
results) in those with and without nephropathy on placebo, irbesartan and combinations of these   
 Placebo in AER 
in range of 20 
to 
200mcg/min 
Irbesartan 
in AER range 
of 20 to 
200mcg/min 
Placebo and 
Irbesartan in 
AER range 20 to 
200mcg/min 
Placebo with 
AER≤80mcg/min & 
Irbesartan with 
 AER > 80mcg/min 
 Ln(AER) Ln(AER) Ln(AER) Ln(AER) 
NEPHROPATHY 
    Average 4.56 4.52 4.54 4.54 
Standard deviation 0.42 0.48 0.45 0.42 
NO NEPHROPATHY 
    Average 3.65 3.65 3.65 3.65 
Standard deviation 0.91 0.91 0.91 0.91 
 
It can be seen that the mean and standard deviations of the AER in those with nephropathy and no 
nephropathy are similar for all four subgroups. This is in keeping with the assumption that the 
distribution in these groups is not affected by the fact that the group was on active treatment or 
control. The distribution of the AER in those with no nephropathy was identical in each column at 
3.65 and 0.91 respectively. This was because the distribution in each case was based on entire 
population of 1,469 patients with diabetes who were considered for the trial and little affected by 
the ‘addition’ of patients who were prevented from developing nephropathy. 
 
7. Dichotomous observations 
The principle of a treatment-independent likelihood of observing an observation for those with and 
without an outcome irrespective of whether the patient was on a placebo or treatment can be 
applied to a dichotomous observation (e.g. that the AER was greater than 80mcg/min. Table 3 shows 
that the likelihood is much the same for the four different categories. Thus the likelihood of an AER 
>80mcg/min at the beginning of the study conditional on the presence of nephropathy at the end of 
the study is 0.655 to 0.667 in all four categories in table 3. Similarly the likelihood of an AER 
≤80mc/min at the beginning of the study conditional on the presence of absence of nephropathy at 
the end of the study is 0.253 to 0.275 in all four categories. 
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Table 3: The likelihood of observing a patient with an AER over 80mcg/min in various populations 
taking placebo or irbesartan 150mg or 300mg daily 
 In those taking 
Placebo in 
entire AER 
range  
In those taking 
Irbesartan in 
entire AER 
range  
In those taking 
Placebo or 
Irbesartan in 
entire AER range  
In those taking Placebo 
with AER≤80mcg/min 
& Irbesartan with  AER 
> 80mcg/min 
If NEPHROPATHY 
    Likelihood of AER> 80mcg/min 20/19=0.655 20/30=0.667 39/59=0.661 19/29=0.655 
No with outcome 19 20 39 20 
Total number 29 30 59 29 
If NO NEPHROPATHY 
    Likelihood of AER> 80mcg/min 42/166=0.253 92/346=0.266 134/512=0.262 47/171=0.275 
No with outcome 42 92 134 47 
Total number 166 346 512 171 
 
8. Constructing curves to display the probability of nephropathy conditional on each AER 
In order to construct curves to display the estimated probability of nephropathy conditional on each 
AER we need to know the estimated distribution of the AER in those patients with nephropathy and 
those without nephropathy. We can estimate these using the means and standard deviations shown 
in the fifth column of table 2. The distributions are shown in figure 1. 
 
We also need to estimate the overall ‘prior’ proportions of patients with nephropathy in those on 
placebo and irbesartan as shown in the bottom row of table 1. (These overall proportions will be 
those ‘prior’ to taking into account each AER likelihood ratio in order to create the posterior 
probability curves showing the estimated probability of nephropathy conditional on each AER). The 
overall ‘prior’ proportions in the bottom row of table 1 were obtained from all the data in the IRMA2 
RCT. Our task is to estimate these proportions from the ‘threshold’ part of this data as shown in the 
5th column of table 3. 
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Log of the Albumin excretion rate 
Figure 1: Likelihood distributions of the log AER in patients 
with and without biochemical nephropathy within 2 years 
Patients with biochemical 
nephropathy within 2 years 
Patients with no biochemical 
nephropathy within 2 years 
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9. The Bayes rule rearrangement 
According to the assumption of treatment independent likelihoods, the estimated odds of 
nephropathy conditional on an AER ≤ 80mcg/min when taking placebo (i.e. 10/124 from Table 1) will 
be equal to the prior odds of nephropathy on placebo multiplied by the likelihood ratio of an AER ≤ 
80mcg/min with respect to nephropathy over ‘no nephropathy’ is: 
(1-0.655)/(1-0.275) = 0.345/0.725 = 0.476 from table 3). 
This means that from the odds version of Bayes rule: 
10/124 = (Prior odds (Neph|Placebo))*0.476) 
If we rearrange the odds version of Bayes rule: 
Prior odds of Nephropathy in those on Placebo = (10/124)/0.476 = 0.169. 
The estimated prior probability of Nephropathy in those on Placebo is therefore 0.169/(1+0.169) = 
0.145. This estimate is based on only the data that would have been obtained by a non-randomised 
threshold study. It is close to the observed proportion in the complete data set of 30/196 = 0.153 as 
shown in Table 1. These and the other estimates are shown in Table 4. The estimates from the non-
randomised study for irbesartan 150mg daily was 10.4% (observed 10.2% in table 1). The estimate 
for irbesartan 300mg daily was 4.2% (the observed proportion was 5.2% in table 1) and on 150mg or 
300mg daily of irbesartan the estimate was 7.9% (observed 7.7% in table 1). There will be wider 
confidence intervals for these estimates compared to those observed in table 1 and the resulting 
curves as they were based on less than all the data that available from the RCT. 
Table 4: Estimation of the ‘prior’ probability of nephropathy on placebo and irbesartan based on 
data from tables 1 and 3 
Observed proportion with 
Nephropathy in those with: 
Conditional 
odds 
Likelihood ratio 
(from column 5 Table 1) 
Estim. odds of Nephropathy 
conditional on medication 
Estim. Prob Neph 
from threshold data 
Observed prob 
Neph from all data 
      
AER≤80&Placebo =10/134 10/124 
(1-0.655)/(1-0.275)= 
(10/29)/(124/171) 
(10)/124)/((1-0.655)/(1-0.275) 
= 0.169 
0.169/(1+0.169) 
 = 0.145 30/196= 0.153 
      
AER>80&Irb 150 or 300 =19/112 19/93 
0.655/0.275= 
(19/29)/(47/171) 
(19/93)/(0.655/0.275) 
= 0.086 
0.0857/(1+0.0857)  
= 0.079 29/379=0.077 
      
AER≤80&Irb 150 = 14/62 14/48 
0.655/0.275= 
 (19/29)/(47/171) 
(14/48)/(0.655/0.275) 
= 0.122 
0.116/(1+0.116)  
= 0.109 19/187 = 0.102 
      
AER≤80&Irb 300 = 5/50 5/45 
0.655/0.275= 
(19/29)/(47/171) 
(5/45)/(0.655/0.275) 
= 0.047 
0.044/(1+0.044)  
= 0.045 10/192 = 0.052 
 
The likelihood ratios in the third column of table 4 can also be estimated from the distributions of 
the AER in figure 1. The threshold of 80mcg/min corresponds to a ln(AER) of 4.38. The proportion of 
the area under the no nephropathy distribution below ln(AER) 4.38 is 0.787 when the mean is 3.65 
and the standard deviation is 0.913. The proportion of the area under the nephropathy distribution 
below ln(AER) 4.38 is 0.360 when the mean is 4.45 and the standard deviation is 0.450. These 
proportions are shown in bold in the third column of figure 5. The corresponding overall proportions 
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are shown in the last column and are slightly different from those in Figure 4. This reflects the result 
of the slightly different assumptions made in the calculations and the small numbers involved when 
the data for the two different doses of irbesartan are analysed separately.   
Table 5: Estimation of the ‘prior’ probability of nephropathy on placebo and irbesartan based on 
data from tables 1 and Figure 1: 
Observed proportion 
with Nephropathy in 
those with: 
Conditional 
odds 
Likelihood ratio (from 
tails in Figure 1) 
Estim. odds of 
Nephropathy conditional 
on medication 
Estim. Prob Neph 
from threshold 
data 
Observed prob 
Neph from all 
data 
      AER≤80&Placebo 
=10/134 10/124 
(1-0.640)/(1-0.213)= 
0.360/0.787 = 0.458 
(10)/124)/(0.360/0.787) = 
0.176 
0.176/(1+0.176) = 
0.150 30/196= 0.153 
      AER>80&Irb 150 or 
300 =19/112 19/93 0.640/0.213= 3.00 
(19/93)/(0.640/0.213)= 
0.068 
0.068/(1+0.068) = 
0.064 29/379=0.077 
      AER≤80&Irb 150 = 
14/62 14/48 0.640/0.213= 3.00 
(14/48)/ (0.640/0.213)= 
0.097 
0.097/(1+0.097) = 
0.089 19/187 = 0.102 
      AER≤80&Irb 300 = 
5/50 5/45 0.640/0.213= 3.00 
(5/45)/ (0.640/0.213) = 
0.037 
0.037/(1+0.037) = 
0.036 10/192 = 0.052 
 
10. Plotting the probabilities of nephropathy for each AER value for each medication 
The estimated prior probabilities allow us to plot the curve showing the probabilities of nephropathy 
for each AER value for placebo, irbesartan 150 mg daily, irbesartan 300 mg daily and for the 
combined group of irbesartan 150 mg or 300mg daily. Thus the probability of nephropathy at a value 
AERi will be 1/(1 + [1/odds Nephropathy] * [1/ Likelihood ratio of AERi for Nephropathy). The odds 
of nephropathy used are those from Table 4. The likelihood ratio of AERi for Nephropathy is the ratio 
of the heights of the curves in Figure 1. In the interest of simplicity, only curves are shown for 
irbesartan for the combined data for the two doses of 150 or 300mg daily.. 
There are 4 curves in figure 2. The dashed curves were calculated using the prior probabilities from 
table 1 based on all the data from the IRMA2 RCT. The prior probability of nephropathy for those on 
placebo from the 6th column of table 4 based on all the data from the RCT was 30/196 = 0.153 and 
for treatment with both doses of irbesartan was 29/379 = 0.077. The dashed curves are based on all 
the RCT data and show the probabilities of nephropathy after 2 years of placebo (the upper dashed 
curve) and irbesartan (the lower dashed curve).  
The unbroken curves are based on the estimated prior probabilities that would have been provided 
by a threshold controlled trial. The upper unbroken continuous curve was based on the estimated 
prior probability of 0.145 of nephropathy after taking placebo (see the 6th column of table 4). The 
lower unbroken continuous curve was based on the estimated prior probability of 0.079 of 
nephropathy after taking irbesartan. 
The dashed curves based on the full data from the RCT and the unbroken curves based on partial 
data that would have been obtained from a threshold trial in figure 2 are very similar. The small 
differences between the curves depend on the small differences between these ‘prior’ probabilities 
(of 0.153 compared to 0.145 for placebo and 0.077 compared to 0.079 for treatment) used to 
calculate them. This is a demonstration of how applying the Bayes rule rearrangement can be used 
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to estimate the result of an RCT from a segmental controlled trial. The curves for irbesartan 150mg 
alone and 300mg alone have been omitted from figure 2. The Irbesartan 150mg daily curve would 
have been above the irbesartan curve and the 300mg daily curve would have been below it. 
 
The small difference between the threshold and RCT curves were due to the small differences 
between the estimated overall proportions of nephropathy on placebo and treatments. These 
differences can be explained from minor stochastic variation. 
The steepness of the curves in figure 2 depends on the discriminating power of the AER. This is 
reflected by differences in the means and variances of the two distributions in figure 1. The means of 
the distributions of a diagnostic test in those with and without an outcome will be superimposed if 
there is no discriminating power. In this situation the curves in figure 2 would have been flat. 
However, in a more powerful test that the AER, the separation of the means of the distributions will 
be greater and the curves will be steeper and rise nearer to one.   
11. The difference between the probability estimates of nephropathy on placebo and treatment  
A clinical decision maker would be interested in the difference between the probable outcome of 
nephropathy on placebo and treatment. This can be found by subtracting the probability of 
nephropathy on placebo from that on treatment at each AER. A curve displaying the difference is 
shown in figure 3. The current ‘upper limit of normal’ for an AER is 20mcg/min but figure 3 shows 
that there is no difference at all between the effect of treatment and placebo at this value above 
which it is customary to offer treatment to prevent nephropathy. This custom is therefore 
unjustified. A difference begins to appear at about 30mcg/min and at an AER of 40mcg/min there is 
a 2.5% absolute risk reduction from treatment compared to placebo on the threshold curve and 3% 
risk reduction on the RCT curve. The maximum risk reduction is about 15% at an AER of 140mcg/min. 
there is a current view is that patients should be informed of these risk reductions and asked to 
participate in shared decision making by balancing these risk reductions with the risk of harm and 
inconvenience of being on long term treatment [12]. 
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Albumin excretion rate in mcg/min 
Figure 2: Estimated probabilities of nephropathy after 2 
years on placebo and treatment from randomised (RCT) 
and simulated 'threshold' (TCT) controlled trials 
Probabilities of nephropathy on Placebo CCT 
Probabilities of nephropathy on Treatment CCT 
Probabilities of nephropathy on Placebo RCT 
Probabilities of nephropathy on Treatment RCT 
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The overall proportion developing nephropathy on irbesartan during the RCT was 19/379 = 0.077 so 
that the relative risk compared to placebo from the RCT was 0.077/0.135 = 0.57, the odds ratio being 
0.462. The overall proportion developing nephropathy on irbesartan during the ‘segmental’ analysis 
was 0.079 so that the relative risk was 0.079/0.145 = 0.54, the odds ratio being 0.506.  
12. Internal validity and assessing the assumption of treatment independent likelihoods 
The internal validity of the probabilities estimated by the above methods depends on the controls in 
(e.g. blinding of subjects and / or assessors) and also on the assumptions made. The data analysed 
‘as if’ a threshold trial had been conducted were part of those used in RCT and so this aspect of 
interval validity was the same as for the RCT. The other aspect of internal validity and source of bias 
is the assumption of treatment independent likelihood distributions and that the distribution of the 
AER in those with and without nephropathy could be modelled with Gaussian or t-distributions using 
the mean and standard deviations in table 2.  
One test of the internal validity of probabilities within a subset is that their average corresponds to 
the overall frequency of that outcome that they seek to predict in the whole set. For example, the 
estimate overall frequency of nephropathy after 2 years on placebo was 0.145. For the 512 AER 
results of all those patients in the original RCT, the average of the 512 estimated probabilities of 
nephropathy on placebo was a slight overestimate of 0.156. This implies that the assumption of 
treatment independent likelihood and that the distributions could be modelled with a Gaussian 
distribution were reasonable but not precisely correct. 
13. Stochastic variation 
The prior probability estimates will be subject to stochastic variation of course. For example, from all 
the RCT data shown in table 1 the estimated prior probability of nephropathy in those on placebo 
was 30/106 = 0.153, the 95% confidence limits being 0.107 and 0.213. The prior probability of 0.145 
from the threshold study was based only on part of the data generated by the RCT so the confidence 
limits for the estimate of 0.145 were estimated in turn to be 0.077 and 0.245. This means therefore 
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Albumin excretion rate in mcg/min 
Figure 3: Difference between estimated probabilities of 
nephropathy on Placebo and Irbesartan for each AER for an RCT 
and a simulated segmental trial 
Differences in probability of nephropathy on placebo and 
treatment from simulated segmental trial 
Differences in probability of nephropathy on placebo and 
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that the curves in figure 2 from the threshold study and from the original RCT could have wide 
confidence intervals. This would also be true for the differences between them as shown in figure 3. 
There will also be stochastic variation in the difference between the means shown in figure 1. If the 
means were the same, then the curves in figure 2 would be flat. If the means were wider apart then 
both curves would be steeper. The stochastic variation would therefore be seen as a tendency for 
the probability curves in Figure 2 to ‘rotate’ from being steeper to being flatter. The details of 
stochastic variation due to the means of the distributions and the ‘overall’ prior probabilities will not 
be discussed in detail in this particular paper. 
14. Varying the outcome 
The purpose of this analysis is not only to show the effect of a treatment (reflected by the constant 
odds ratio between the curves (or the relative risk if desired) but also the shape of the curves and 
the point at which a clinical difference appears (i.e. at about 40mcg/min in figures 2 and 3). This 
approach can also be used to examine the effect of using different test results, including those based 
on multivariable analyses and different entry criteria. In contrast to this, the regression discontinuity 
design provides evidence of efficacy at the threshold alone. This is in the form of a difference 
between the means and variance of a continuous outcome measure in those with and without 
treatment. The threshold analysis described here provided an estimated probability with a 
dichotomous outcome at the AER threshold of 80mcg/min and all other AER points too.  
This analysis based on a Bayes rule rearrangement could be repeated for different outcomes (i.e. 
instead of an AER over 200mcg/min at 2 years signifying ‘nephropathy’, the analysis could be 
repeated with an outcome of an AER of over 350, 300, 250, 200, 150, 100 and 50mcg/min for 
example). This would create a family of curves that would represent an overall picture and allow the 
probability of the AER falling within any range to be estimated.  
15. Comparison of ‘treatment independent likelihood’ and ‘regression discontinuity method’ 
The ‘regression discontinuity’ method displays the distributions of the outcome marker on 
treatment and no treatment at the threshold. The value of the outcome marker could be 
dichotomised into ‘high’ or ‘low’ or ‘positive’ or ‘negative’ and probabilities estimated of the 
outcome marker being ‘positive’ or ‘high’. For example, if the outcome marker were an AER at 2 
years, then it would be possible to estimate the probability of the AER being at least 200mcg/min on 
placebo and treatment. This would in turn allow the odds ratio or relative risk to be estimated. 
However, it would not be possible to construct the probability curves without applying the Bayes 
rule rearrangement. Furthermore, the method based on Bayes rule rearrangement and the 
assumption of treatment independent likelihoods is much simpler to perform. 
16. Clinical audits, ‘real-world evidence’ and the assessment of external validity 
One of the assumptions made during analysis of a ‘segmental’ study design is that the distribution of 
diagnostic test result in some outcome is the same in those on a treatment or not on treatment. This 
means that if patients were started on treatments at different diagnostic test result thresholds (e.g. 
instead of all at an AER of 80mcg/min, some were started at 70, some at 80 some at 90mcg/min etc.) 
then this would not affect the estimated distributions of diagnostic test result in those with and 
without some outcome. This is termed a ‘fuzzy’ effect during ‘regression discontinuity’ analyses [7, 
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8] and impedes its application. This is not the case for the method described here based on an 
assumption of treatment independent likelihoods and a Bayes rearrangement which can cope with 
such ‘fuzzy’ data as it is based on the assumption that the distributions are the same irrespective of 
whether they are treatment or control. However the estimation o the overall or proportions ‘prior’ 
to knowing the AER result can be estimated form other segments of data away from the ‘fuzzy’ 
areas.  
The patients and assessors of response in a ‘real-world’ study may not be blinded so that 
subjectively reported outcomes might be affected by a placebo effect (less so for biochemical and 
other objective outcomes as in this study). However, the approach could be used to monitor and 
audit the effect of treatments and diagnostic tests in the community. It could also be used to assess 
the external validity of an RCT (which is a concern [5]) by observing what happens when a treatment 
is given or not during day to day care. 
17. Conclusion 
Provided that suitable controls are in place (e.g. use of placebo arms and ‘double blinding’) it 
appears that a study of this kind might provide an acceptable estimate of the result of an RCT or to 
be a substitute if an RCT is not possible. It might also used to assess the performance of various 
diagnostic tests in predicting outcomes on treatment and placebo. The approach might be applicable 
to so-called pragmatic ‘real-world’ assessments or an audit of the performance of tests and 
treatments during day to day care to assess the external validity of previously tightly-controlled 
clinical trials. 
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